We are live on ! Find out more

158 hedge funds and large institutions have $2.39B invested in Insmed in 2019 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 48 increasing their positions, 49 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

291% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 11

121% more capital invested

Capital invested by funds: $1.08B → $2.39B (+$1.31B)

40% more funds holding in top 10

Funds holding in top 10: 57 (+2)

25% more funds holding

Funds holding: 126158 (+32)

20% more call options, than puts

Call options by funds: $25.2M | Put options by funds: $21M

0.9% less ownership

Funds ownership: 106.95%106.05% (-0.9%)

2% less repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 49

Holders
158
Holders Change
+32
Holders Change %
+25.4%
% of All Funds
3.42%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.15%
New
43
Increased
48
Reduced
49
Closed
11
Calls
$25.2M
Puts
$21M
Net Calls
+$4.25M
Net Calls Change
+$20.8M

INSM Hedge Fund Activity: Q1 2019 in Review

158 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q1 2019, worth a combined $2.39B — up 121% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new INSM positions and 11 closed out — a net gain of 32 holders — while 48 added to existing stakes and 49 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $30.3M. The largest seller was VOYA Investment Management, cutting an estimated $21.9M.

  • 158 institutional investors held Insmed (INSM) as of Q1 2019, up from 126 in Q4 2018.
  • Funds reported $2.39B of Insmed stock for Q1 2019, up 121% quarter-over-quarter.
  • 43 funds opened new Insmed positions in Q1 2019 and 11 closed out, a net change of +32 holders.
  • The largest Insmed buyer in Q1 2019 was Vivo Capital, an estimated $30.3M added.
  • The largest Insmed seller in Q1 2019 was VOYA Investment Management, an estimated $21.9M sold.

Based on aggregated 13F filings for Q1 2019.